The U.S. Food and Drug Administration (FDA) has given its approval to Tzield (teplizumab), a groundbreaking drug aimed at delaying the progression of type 1 diabetes. This approval marks a significant advancement in the treatment of type 1 diabetes, a condition affecting approximately 1.9 million Americans, where the immune system attacks insulin-producing cells, leading to elevated glucose levels that require daily monitoring and insulin injections.
Tzield is specifically designed for patients older than eight years who are in stage two of type 1 diabetes. It works by deactivating the immune cells that attack insulin-producing cells and increasing the proportion of cells that help moderate the immune response. This mechanism offers the potential to delay the onset of stage three type 1 diabetes, providing patients with a reprieve from the disease's daily challenges.
Dr. John Sharretts of the FDA highlighted the importance of this new treatment option, stating, "Today’s approval of a first-in-class therapy adds an important new treatment option for certain at-risk patients. The drug’s potential to delay clinical diagnosis of type 1 diabetes may provide patients with months to years without the burdens of disease."
However, the use of Tzield is not without risks. Potential side effects include an overly aggressive response to the medication, infections, decreased levels of lymphocytes (a type of white blood cell), headaches, and rash. These risks underscore the need for careful consideration and monitoring when prescribing Tzield.
In terms of cost, Tzield is priced at $13,850 per vial, with a 14-day treatment course amounting to $193,900. This pricing has been noted as higher than market expectations, raising concerns about accessibility for patients in need of this innovative treatment.
